These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 22653206)
1. Chemical structure does not define obviousness. Harrison C Nat Rev Drug Discov; 2012 Jun; 11(6):432-3. PubMed ID: 22653206 [No Abstract] [Full Text] [Related]
2. Patents: a threat to innovation? Manocaran M Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557 [No Abstract] [Full Text] [Related]
3. Intellectual property. Drug patents at the Supreme Court. Hemphill CS; Sampat B Science; 2013 Mar; 339(6126):1386-7. PubMed ID: 23520096 [No Abstract] [Full Text] [Related]
4. Intellectual property. Balancing innovation and access: patent challenges tip the scales. Higgins MJ; Graham SJ Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944 [No Abstract] [Full Text] [Related]
6. IP litigation in China could drive innovation. Jia H Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539 [No Abstract] [Full Text] [Related]
7. Big Pharma vs India’s Patent Office. Pharm Pat Anal; 2012 Nov; 1(5):529. PubMed ID: 24236921 [No Abstract] [Full Text] [Related]
8. [Similarity of biotechnology-derived drugs: regulatory framework and specificity]. Prugnaud JL Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566 [TBL] [Abstract][Full Text] [Related]
9. Taking TRIPS to India--Novartis, patent law, and access to medicines. Mueller JM N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473 [No Abstract] [Full Text] [Related]
10. Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision. Dhulap S; Kulkarni MG Expert Opin Ther Pat; 2021 Oct; 31(10):951-963. PubMed ID: 33993810 [No Abstract] [Full Text] [Related]
11. Global health and university patents. Kapczynski A; Crone ET; Merson M Science; 2003 Sep; 301(5640):1629. PubMed ID: 14500943 [No Abstract] [Full Text] [Related]
12. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents. Teitelbaum R; Cohen M Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990 [No Abstract] [Full Text] [Related]
13. Pharmaceutical Portfolio & Product Life Cycle Management--SMi's fourth annual conference. 29-30 June 2009, London, UK. Beecher N IDrugs; 2009 Sep; 12(9):558-60. PubMed ID: 19697274 [No Abstract] [Full Text] [Related]
14. The strategy of enantiomer patents of drugs. Agranat I; Wainschtein SR Drug Discov Today; 2010 Mar; 15(5-6):163-70. PubMed ID: 20116449 [TBL] [Abstract][Full Text] [Related]
15. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry. Burshtein S Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562 [No Abstract] [Full Text] [Related]